ASPEN PHAR.UN.ADR /1 O.N. (LDZU) - Net Assets
Based on the latest financial reports, ASPEN PHAR.UN.ADR /1 O.N. (LDZU) has net assets worth €81.09 Billion EUR (≈ $94.80 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€128.04 Billion ≈ $149.70 Billion USD) and total liabilities (€46.96 Billion ≈ $54.90 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is ASPEN PHAR.UN.ADR /1 O.N.'s balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €81.09 Billion |
| % of Total Assets | 63.33% |
| Annual Growth Rate | 6.17% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.55 |
ASPEN PHAR.UN.ADR /1 O.N. - Net Assets Trend (2022–2025)
This chart illustrates how ASPEN PHAR.UN.ADR /1 O.N.'s net assets have evolved over time, based on quarterly financial data. Check ASPEN PHAR.UN.ADR /1 O.N. tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
The table below shows the annual net assets of ASPEN PHAR.UN.ADR /1 O.N. from 2022 to 2025. For live valuation and market cap data, see ASPEN PHAR.UN.ADR /1 O.N. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €84.89 Billion ≈ $99.25 Billion |
+0.04% |
| 2024-06-30 | €84.86 Billion ≈ $99.21 Billion |
-1.59% |
| 2023-06-30 | €86.24 Billion ≈ $100.82 Billion |
+21.56% |
| 2022-06-30 | €70.94 Billion ≈ $82.94 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ASPEN PHAR.UN.ADR /1 O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €58.09 Billion | 68.43% |
| Other Components | €26.80 Billion | 31.57% |
| Total Equity | €84.89 Billion | 100.00% |
ASPEN PHAR.UN.ADR /1 O.N. Competitors by Market Cap
The table below lists competitors of ASPEN PHAR.UN.ADR /1 O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
National HealthCare Corporation
NYSE MKT:NHC
|
$2.95 Billion |
|
Anadolu Efes Biracilik ve Malt Sanayi AS
IS:AEFES
|
$2.95 Billion |
|
Star Bulk Carriers Corp
NASDAQ:SBLK
|
$2.95 Billion |
|
BBVA Banco Frances SA ADR
NYSE:BBAR
|
$2.95 Billion |
|
Relay Therapeutics Inc
NASDAQ:RLAY
|
$2.95 Billion |
|
Bank of Queensland Ltd
AU:BOQ
|
$2.94 Billion |
|
Kesko Oyj
HE:KESKOA
|
$2.94 Billion |
|
First BanCorp
F:OLWN
|
$2.94 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ASPEN PHAR.UN.ADR /1 O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 84,861,000,000 to 84,893,000,000, a change of 32,000,000 (0.0%).
- Net loss of 1,083,000,000 reduced equity.
- Dividend payments of 1,601,000,000 reduced retained earnings.
- Share repurchases of 68,000,000 reduced equity.
- Other factors increased equity by 2,784,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.08 Billion | -1.28% |
| Dividends Paid | €1.60 Billion | -1.89% |
| Share Repurchases | €68.00 Million | -0.08% |
| Other Changes | €2.78 Billion | +3.28% |
| Total Change | €- | 0.04% |
Book Value vs Market Value Analysis
This analysis compares ASPEN PHAR.UN.ADR /1 O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €159.44 | €6.90 | x |
| 2023-06-30 | €194.12 | €6.90 | x |
| 2024-06-30 | €191.03 | €6.90 | x |
| 2025-06-30 | €191.19 | €6.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ASPEN PHAR.UN.ADR /1 O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.50%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.60x
- Recent ROE (-1.28%) is below the historical average (4.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 9.15% | 16.81% | 0.35x | 1.57x | €-606.20 Million |
| 2023 | 6.06% | 12.84% | 0.30x | 1.56x | €-3.40 Billion |
| 2024 | 5.19% | 9.85% | 0.32x | 1.64x | €-4.08 Billion |
| 2025 | -1.28% | -2.50% | 0.32x | 1.60x | €-9.57 Billion |
Industry Comparison
This section compares ASPEN PHAR.UN.ADR /1 O.N.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,540,713,615
- Average return on equity (ROE) among peers: -38.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ASPEN PHAR.UN.ADR /1 O.N. (LDZU) | €81.09 Billion | 9.15% | 0.58x | $2.95 Billion |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $59.93 Billion | 4.62% | 0.96x | $1.17 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.05 Billion | 11.11% | 0.41x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $4.89 Million | -63.10% | 0.49x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $191.93 Million | -51.86% | 1.16x | $141.92 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-9.91 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $26.34 Million | -20.49% | 0.14x | $8.71 Million |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $61.59 Million |
About ASPEN PHAR.UN.ADR /1 O.N.
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic ag… Read more